RGEN
Repligen CorpCompany with tickers: RGEN
Market Cap
$8.19B
Shares Outstanding
56,407,740
CIK
730272
CUSIP
759916109
13F Activity (30d)
20 filings
10 filers
Website
Visit website
Investor Relations
Investor relations
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Interest & Dividend Income | — | ||||
| Net Interest Income | — | ||||
| Noninterest Income | — | ||||
| Total Net Revenue | — | ||||
| Premiums Earned (Net) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $14,458,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Operating Income | $15,940,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Net Income | $8,333,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Basic) | $0.15 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Diluted) | $0.15 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |